177 related articles for article (PubMed ID: 38509691)
1.
Romussi S; Giunti S; Andersen N; De Rosa MJ
Expert Opin Drug Discov; 2024 May; 19(5):565-585. PubMed ID: 38509691
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery: Insights from the invertebrate Caenorhabditis elegans.
Giunti S; Andersen N; Rayes D; De Rosa MJ
Pharmacol Res Perspect; 2021 Apr; 9(2):e00721. PubMed ID: 33641258
[TBL] [Abstract][Full Text] [Related]
3. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
Corti S; Faravelli I; Cardano M; Conti L
Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
[TBL] [Abstract][Full Text] [Related]
4. The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
Struzyna LA; Watt ML
Mol Pharmacol; 2021 Apr; 99(4):256-265. PubMed ID: 33547249
[TBL] [Abstract][Full Text] [Related]
5. Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases.
Ma L; Zhao Y; Chen Y; Cheng B; Peng A; Huang K
Eur J Pharmacol; 2018 Jan; 819():169-180. PubMed ID: 29208474
[TBL] [Abstract][Full Text] [Related]
6. C. elegans in high-throughput drug discovery.
O'Reilly LP; Luke CJ; Perlmutter DH; Silverman GA; Pak SC
Adv Drug Deliv Rev; 2014 Apr; 69-70():247-53. PubMed ID: 24333896
[TBL] [Abstract][Full Text] [Related]
7. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.
Kim W; Hendricks GL; Lee K; Mylonakis E
Expert Opin Drug Discov; 2017 Jun; 12(6):625-633. PubMed ID: 28402221
[TBL] [Abstract][Full Text] [Related]
8. Whole animal HTS of small molecules for antifungal compounds.
Muhammed M; Arvanitis M; Mylonakis E
Expert Opin Drug Discov; 2016; 11(2):177-84. PubMed ID: 26593386
[TBL] [Abstract][Full Text] [Related]
9. Massively parallel C. elegans tracking provides multi-dimensional fingerprints for phenotypic discovery.
Perni M; Challa PK; Kirkegaard JB; Limbocker R; Koopman M; Hardenberg MC; Sormanni P; Müller T; Saar KL; Roode LWY; Habchi J; Vecchi G; Fernando N; Casford S; Nollen EAA; Vendruscolo M; Dobson CM; Knowles TPJ
J Neurosci Methods; 2018 Aug; 306():57-67. PubMed ID: 29452179
[TBL] [Abstract][Full Text] [Related]
10. Caenorhabditis elegans: a versatile platform for drug discovery.
Artal-Sanz M; de Jong L; Tavernarakis N
Biotechnol J; 2006 Dec; 1(12):1405-18. PubMed ID: 17109493
[TBL] [Abstract][Full Text] [Related]
11. Cell death assays for neurodegenerative disease drug discovery.
Linsley JW; Reisine T; Finkbeiner S
Expert Opin Drug Discov; 2019 Sep; 14(9):901-913. PubMed ID: 31179783
[No Abstract] [Full Text] [Related]
12. Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z.
Gosai SJ; Kwak JH; Luke CJ; Long OS; King DE; Kovatch KJ; Johnston PA; Shun TY; Lazo JS; Perlmutter DH; Silverman GA; Pak SC
PLoS One; 2010 Nov; 5(11):e15460. PubMed ID: 21103396
[TBL] [Abstract][Full Text] [Related]
13. Invertebrate animal models of diseases as screening tools in drug discovery.
Ségalat L
ACS Chem Biol; 2007 Apr; 2(4):231-6. PubMed ID: 17455900
[TBL] [Abstract][Full Text] [Related]
14. Streamlining drug discovery assays for cardiovascular disease using zebrafish.
Pott A; Rottbauer W; Just S
Expert Opin Drug Discov; 2020 Jan; 15(1):27-37. PubMed ID: 31570020
[No Abstract] [Full Text] [Related]
15. Comparative Analysis of Experimental Methods to Quantify Animal Activity in Caenorhabditis elegans Models of Mitochondrial Disease.
Lavorato M; Mathew ND; Shah N; Nakamaru-Ogiso E; Falk MJ
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871460
[TBL] [Abstract][Full Text] [Related]
16. Discovery of small molecule inhibitors for the C. elegans caspase CED-3 by high-throughput screening.
Brantley SJ; Cotten SW; Lamson DR; Smith GR; Liu R; Williams KP
Biochem Biophys Res Commun; 2017 Sep; 491(3):773-779. PubMed ID: 28733033
[TBL] [Abstract][Full Text] [Related]
17. A rapid chemical-genetic screen utilizing impaired movement phenotypes in C. elegans: Input into genetics of neurodevelopmental disorders.
Schmeisser K; Fardghassemi Y; Parker JA
Exp Neurol; 2017 Jul; 293():101-114. PubMed ID: 28373024
[TBL] [Abstract][Full Text] [Related]
18. Large-scale microfluidics providing high-resolution and high-throughput screening of Caenorhabditis elegans poly-glutamine aggregation model.
Mondal S; Hegarty E; Martin C; Gökçe SK; Ghorashian N; Ben-Yakar A
Nat Commun; 2016 Oct; 7():13023. PubMed ID: 27725672
[TBL] [Abstract][Full Text] [Related]
19. Automated Platform for Long-Term Culture and High-Content Phenotyping of Single C. elegans Worms.
Atakan HB; Xiang R; Cornaglia M; Mouchiroud L; Katsyuba E; Auwerx J; Gijs MAM
Sci Rep; 2019 Oct; 9(1):14340. PubMed ID: 31586133
[TBL] [Abstract][Full Text] [Related]
20. Practical High-Throughput Method to Screen Compounds for Anthelmintic Activity against
Taki AC; Byrne JJ; Boag PR; Jabbar A; Gasser RB
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
